

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/Capplus enhanced with utility model patents from China
NEWS	6	JUL 16	Capplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/Capplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:01:12 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:01:21 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0
DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10591757a.str



chain nodes :
 12 19 20 21
 ring nodes :
 1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
 chain bonds :
 7-12 12-13 16-19 17-20 18-21
 ring bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
 17-18
 exact/norm bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 7-12 8-9 12-13 13-14 13-18 14-15
 15-16 16-17 16-19 17-18 17-20 18-21
 isolated ring systems :
 containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR





G1 C,N

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10591757a.str



chain nodes :
 12 19 20 21
 ring nodes :
 1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
 chain bonds :
 7-12 12-13 16-19 17-20 18-21
 ring bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
 17-18
 exact/norm bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 7-12 8-9 12-13 13-14 13-18 14-15
 15-16 16-17 16-19 17-18 17-20 18-21
 isolated ring systems :
 containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS

L2 STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 13:02:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 132 TO 668
PROJECTED ANSWERS: 4 TO 200

L3 4 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 13:02:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 376 TO ITERATE

100.0% PROCESSED 376 ITERATIONS 88 ANSWERS
SEARCH TIME: 00.00.01

L4 88 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 13:02:15 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14 full


L5 1 L4

=> d ibib abs hitstr tot


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1004761 CAPLUS
DOCUMENT NUMBER: 143:306497
TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotsuka; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,			
ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1950389	A	20070418	CN 2005-80014287	20050303
BR 200508243	A	20070724	BR 2005-8243	20050303
MX 2006PA09899	A	20061211	MX 2006-PA9899	20060831
US 2007191289	A1	20070816	US 2006-591757	20060901
IN 2006DN05080	A	20070622	IN 2006-DN5080	20060904
PRIORITY APPL. INFO.:			JP 2004-61426	A 20040304
			WO 2005-JP4145	W 20050303

OTHER SOURCE(S): MARPAT 143:306497
GI




L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864846-28-6 CAPLUS
CN β -D-Glucopyranoside, 4-[2-{4-[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



IT 864844-07-5P 864844-08-6P 864844-09-7P
864844-14-4P 864844-15-5P 864844-16-6P

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β -D-glucopyranosides and 1H-indazol-3-yl β -D-glucopyranosides (I) (R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxy-C1-6 alkyl, C2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkenyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkenylene, C1-6 alkylene-O-, C1-6 alkylene-S-, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = O1, O2; E1 = H, F, OH; E2 = H, F, Me, HOCH2) are prepared. These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of

75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3M, 2 mg Pd(OAc)2, 6 mg tris[2-methylphenyl]phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg

4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl- β -D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50°C overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β -D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α -D-glucopyranoside CS2-5E cells.

IT 864844-68-8P 864846-28-6P
RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as

inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864844-68-8 CAPLUS
CN β -D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-{4-[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

864844-17-7P 864844-18-8P 864844-19-9P
864844-20-2P 864844-22-4P 864844-23-5P
864844-25-7P 864844-27-9P 864844-28-0P
864844-29-1P 864844-30-4P 864844-32-6P
864844-34-8P 864844-36-0P 864844-37-1P
864844-38-2P 864844-39-3P 864844-41-7P
864844-42-8P 864844-43-9P 864844-44-0P
864844-45-1P 864844-46-2P 864844-47-3P
864844-48-4P 864844-49-5P 864844-50-8P
864844-51-9P 864844-52-0P 864844-53-1P
864844-54-2P 864844-55-3P 864844-56-4P
864844-58-6P 864844-62-2P 864844-63-3P
864844-69-9P 864844-70-2P 864844-71-3P
864844-72-4P 864844-73-5P 864844-74-6P
864844-75-7P 864844-76-8P 864844-77-9P
864844-78-0P 864844-79-1P 864844-80-4P
864844-81-5P 864844-82-6P 864844-83-7P
864844-84-8P 864844-85-9P 864844-86-0P
864844-87-1P 864844-88-2P 864844-89-3P
864844-90-6P 864844-95-1P 864844-96-2P
864844-97-3P 864844-98-4P 864844-99-5P
864845-00-1P 864845-01-2P 864845-02-3P
864845-04-5P 864845-05-6P 864845-06-7P
864845-07-8P 864845-08-9P 864845-09-0P
864845-10-3P 864845-12-5P 864845-13-6P
864845-14-7P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)


RN 864844-07-5 CAPLUS
CN β -D-Glucopyranoside, 4-(2-phenylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-08-6 CAPLUS
CN β -D-Glucopyranoside, 4-[2-{4-(hydroxy-3-methylphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-09-7 CAPLUS
CN β -D-Glucopyranoside, 4-[2-(4-pyridinyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-14-4 CAPLUS
CN β -D-Glucopyranoside, 4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-17-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β -D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-18-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β -D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-N-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-15-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β -D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-16-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetic acid, 3-(β -D-glucopyranosyloxy)-4-[2-(4-(phenylmethoxy)phenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-19-9 CAPLUS
CN β -D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-20-2 CAPLUS
CN β -D-Glucopyranoside, 1-[2-hydroxyethyl]-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-22-4 CAPLUS
CN Propanamide, 2-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl]phenoxy]propyl]amino]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-23-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-27-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)


Absolute stereochemistry.




RN 864844-28-0 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(2-methoxyethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 864844-25-7 CAPLUS
CN Benzenebutanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-29-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-30-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-32-6 CAPLUS
CN 1H-pyrazolo[3,4-b]pyridine-1-butanimide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-34-8 CAPLUS
CN β-D-glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(3-hydroxypropyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-38-2 CAPLUS
CN β-D-glucopyranoside, 1-[2-(dimethylamino)ethyl]-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-39-3 CAPLUS
CN β-D-glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-36-0 CAPLUS
CN β-D-glucopyranoside, 1-(3-aminopropyl)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)


Absolute stereochemistry.




RN 864844-37-1 CAPLUS
CN Acetamide, 2-amino-N-[3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-1-yl]propyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 864844-41-7 CAPLUS
CN β-D-glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-42-8 CAPLUS
CN β-D-Glucopyranoside, 1-ethyl-4-[2-(4-methoxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-43-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-44-0 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-45-1 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-46-2 CAPLUS
CN Glycine, N-[(3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-47-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-48-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(3-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-49-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-50-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(3-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-51-9 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-[2-(4-methylphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-52-0 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-[2-(3-methylphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-53-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-54-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-([4-hydroxyphenyl]ethynyl)-1-(1-methylethyl)-1H-indazol-3-yl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-55-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-([3-hydroxyphenyl]ethynyl)-1-(1-methylethyl)-1H-indazol-3-yl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-56-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-([4-hydroxy-3-methylphenyl]ethynyl)-1-(1-methylethyl)-1H-indazol-3-yl] (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-58-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-62-2 CAPLUS
CN β-D-Glucopyranoside, 1-((2-hydroxyethyl)-4-([2-((3-hydroxypropoxy)phenyl)ethyl]-1H-indazol-3-yl)) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-63-3 CAPLUS
CN β-D-Glucopyranoside, 4-([2-((3-hydroxypropoxy)phenyl)ethyl]-1H-indazol-3-yl) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-71-3 CAPLUS
CN β-D-Glucopyranoside, 4-([2-([4-([2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino)propoxy]phenyl)ethyl]-1H-indazol-3-yl)) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-72-4 CAPLUS
CN β-D-Glucopyranoside, 1-((2-hydroxyethyl)-4-([2-([4-([2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino)propoxy]phenyl)ethyl]-1H-indazol-3-yl)) (CA INDEX NAME)




RN 864844-69-9 CAPLUS
CN Propanamide, 3-([3-([4-([2-((β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl)ethyl]phenoxy)propyl]amino)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-70-2 CAPLUS
CN β-D-Glucopyranoside, 4-([2-([4-([2-((2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino)propoxy]phenyl)ethyl]-1H-indazol-3-yl)) (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-73-5 CAPLUS
CN β-D-Glucopyranoside, 4-([2-([4-([2-((2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino)propoxy]phenyl)ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl)) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-74-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 864844-75-7 CAPLUS
CN Propanamide, 2-[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.

PAGE 2-A




RN 864844-77-9 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-78-0 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.




RN 864844-76-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A



RN 864844-79-1 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864844-80-4 CAPLUS
CN β -D-Glucopyranoside, 4-[2-[4-[2-([2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino)ethoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 864844-81-5 CAPLUS
CN β -D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[2-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 864844-84-8 CAPLUS
CN β -D-Glucopyranoside, 4-[2-[3-[3-([2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino)propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 864844-85-9 CAPLUS
CN β -D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 864844-82-6 CAPLUS
CN β -D-Glucopyranoside, 4-[2-[3-[2-([2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino)ethoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-83-7 CAPLUS
CN β -D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[2-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 864844-86-0 CAPLUS
CN β -D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[3-([2-hydroxyethyl]amino)propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-87-1 CAPLUS
CN β -D-Glucopyranoside, 4-[2-[4-[3-aminopropoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-88-2 CAPLUS
CN β -D-Glucopyranoside, 4-[2-[4-(2-aminoethoxy)phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-89-3 CAPLUS
CN β -D-Glucopyranoside, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


RN 864844-95-1 CAPLUS
CN Benzenebutanamide, 4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-96-2 CAPLUS
CN Benzenepentanamide, 4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864844-90-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(β -D-glucopyranosyloxy)-4-[2-[4-[3-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



RN 864844-97-3 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864844-98-4 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-oxo-2-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864844-99-5 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864845-00-1 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 864845-04-5 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864845-05-6 CAPLUS
CN Benzenepentanamide, 4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864845-01-2 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864845-02-3 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864845-06-7 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(beta-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864845-07-8 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzenebutanamide, 4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-08-9 CAPLUS
 CN Benzenebutanamide, N-(1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl)-4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864845-09-0 CAPLUS


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzenebutanamide, N-(1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl)-4-[2-[3-(β -D-glucopyranosyloxy)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-13-6 CAPLUS
 CN 1H-Indazole-1-acetamide, 4-[2-[4-[4-[[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]amino]-4-oxobutyl]phenyl]ethyl]-3-(β -D-glucopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864845-14-7 CAPLUS
 CN β -D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzenebutanamide, N-[2-(4-ethyl-1-piperazinyl)-1,1-dimethyl-2-oxoethyl]-4-[2-[3-(β -D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864845-10-3 CAPLUS
 CN 1H-Indazole-1-acetamide, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-3-(β -D-glucopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864845-12-5 CAPLUS

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 864845-32-9P 864845-35-2P 864845-66-9P
 864845-67-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)
 RN 864845-32-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-1-carboxamide, 3-(β -D-glucopyranosyloxy)-4-[2-[4-(phenylmethoxy)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864845-35-2 CAPLUS
 CN β -D-Glucopyranoside, 4-[2-[4-(phenylmethoxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 864845-66-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-azidopropoxy)phenyl]ethyl]-1H-indazole-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-67-0 CAPLUS
CN 1H-indazole-1-acetamide, 4-[2-[4-(3-azidopropoxy)phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:01:12 ON 12 DEC 2007)

FILE 'REGISTRY' ENTERED AT 13:01:21 ON 12 DEC 2007

L1 STRUCTURE UPLOADED

L2 STRUCTURE UPLOADED

L3 4 S L1

L4 88 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:02:15 ON 12 DEC 2007

L5 1 S L4 FULL

=> log

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.21

178.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-0.78

STN INTERNATIONAL LOGOFF AT 13:03:17 ON 12 DEC 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 6 JUL 16 Capplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 Capplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds
NEWS 25 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 26 NOV 19 WPIX enhanced with XML display format
NEWS 27 NOV 30 ICSD reloaded with enhancements
NEWS 28 DEC 04 LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:54:46 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:54:57 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10591757.str



chain nodes :
 12 19 20 21 22 24
 ring nodes :
 1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
 chain bonds :
 6-22 7-12 12-13 16-19 17-20 18-21 22-24
 ring bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
 17-18
 exact/norm bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 6-22 7-8 7-12 8-9 12-13 13-14 13-18
 14-15 15-16 16-17 16-19 17-18 17-20 18-21 22-24
 isolated ring systems :
 containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS
 22:CLASS 24:Atom


Generic attributes :
24:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:56:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 44 TO 476

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:56:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 190 TO ITERATE

100.0% PROCESSED 190 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.00

173.21

FILE 'CAPLUS' ENTERED AT 12:56:27 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25

FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 1 L3


=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2005:1004761 CAPLUS
 DOCUMENT NUMBER: 143:306497
 TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
 INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotsugu; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
 PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,			
ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1950389	A	20070418	CN 2005-80014287	20050303
BR 2005008243	A	20070724	BR 2005-8243	20050303
MX 2006PA09899	A	20061211	MX 2006-PA9899	20060831
US 2007191289	A1	20070816	US 2006-591757	20060901
IN 2006DN05080	A	20070622	IN 2006-DN5080	20060904
PRIORITY APPLN. INFO.:			JP 2004-61426	A 20040304
			WO 2005-JP4145	W 20050303

OTHER SOURCE(S): MARPAT 143:306497
 GI



L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) [R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxy-C1-6 alkyl, CO2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; O = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S-, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2] are prepared. These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.

IT 864845-14-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)
 RN 864845-14-7 CAPLUS
 CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (CA INDEX NAME)
 Absolute stereochemistry.

=> d his

(FILE 'HOME' ENTERED AT 12:54:46 ON 12 DEC 2007)

FILE 'REGISTRY' ENTERED AT 12:54:57 ON 12 DEC 2007

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 1 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:56:27 ON 12 DEC 2007

L4 1 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.74

178.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-0.78

STN INTERNATIONAL LOGOFF AT 12:56:48 ON 12 DEC 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:16:25 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:17:14 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10591757a.str



chain nodes :
 12 13 15
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 6-13 7-12 13-15
 ring bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9
 exact/norm bonds :
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 6-13 7-8 7-12 8-9 13-15
 isolated ring systems :
 containing 1 :

G1:C,N

G2:C,O,S,N


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
 13:CLASS 15:Atom
 Generic attributes :
 15:
 Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:17:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 319 TO ITERATE

100.0% PROCESSED 319 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5309 TO 7451

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:17:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6419 TO ITERATE

100.0% PROCESSED 6419 ITERATIONS

17 ANSWERS

SEARCH TIME: 00.00.01

L3 17 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 13:17:40 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2007:593127 CAPLUS

DOCUMENT NUMBER:

147:31098

TITLE: Preparation of 3-amino-1-arylpropylindoles and aza-substituted indoles as biogenic monoamine

reuptake

inhibitors

INVENTOR(S):

Iyer, Pravin; Lucas, Matthew C.; Schoenfeld, Ryan

PATENT ASSIGNEE(S):

Craig; Villa, Maria; Weikert, Robert James

SOURCE:

Roche Palo Alto LLC, USA

DOCUMENT TYPE:

U.S. Pat. Appl. Publ., 113pp.

LANGUAGE:

CODEN: USXXCO

FAMILY ACC. NUM. COUNT:

Patent

PATENT INFORMATION:

English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007123527	A1	20070531	US 2006-605528	20061129
WO 2007062996	A1	20070607	WO 2006-EP68646	20061120

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.:


US 2005-741266P

P 20051130

OTHER SOURCE(S):


MARPAT 147:31098

GI




AB The title compds. including 3-amino-1-arylpropylindoles and 3-amino-1-arylpropylindazoles [I: p = 1, 2; Y = N, CR; R = H, alkyl; Ar = each (un)substituted indolyl, indazolyl, pyrrolo[2,3-b]pyridyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, indolinyl, or 1,3-dihydroindol-2-onyl; R1 = each (un)substituted Ph, naphthyl, indolyl, indazolyl, pyridinyl, thienyl, furanyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, arylalkyl, or heteroarylalkyl, cycloalkyl, branched alkyl; R2 and R3 = H, alkyl, hydroxyalkyl, alkoxyalkyl, benzyl; or R2 and R3 together with the nitrogen to which they are attached may form an optionally substituted four to

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 938061-97-3 CAPLUS

CN 1H-Indazole-4-propanamide, 3-methoxy-N-methyl-β-phenyl- (CA INDEX NAME)



IT 938059-60-0P, N-(3-(3-Methoxy-1H-indazol-4-yl)-3-phenylpropyl)methylamine monotrifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-amino-1-arylpropylindoles and aza-substituted indoles as biogenic monoamine reuptake inhibitors for treating depression, anxiety, or pain)


RN 938059-60-0 CAPLUS

CN 1H-Indazole-4-propanamide, 3-methoxy-N-methyl-γ-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 938059-59-7

CMF C18 H21 N3 O



CM 2

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

seven membered ring that optionally includes an addnl. heteroatom

selected

from N, O, and S; Ra = H, F, alkyl; Rb = H, alkyl, HO, alkoxy, F, hydroxyalkyl; Rc, Rd = H, alkyl; or Rc and Rd together form :O, :S, or :NRf; Rf = H, alkyl, HO, alkoxy; or one of R2 and R3 together with one of Ra and Rb or one of Rc and Rd together with the atoms to which they are attached may form a four to six membered ring that optionally includes an addnl. heteroatom selected from O, N and S) or pharmaceutically

acceptable

salts thereof are prepd. These compds. are effective as serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, dopamine

reuptake

inhibitors, and/or dual reuptake inhibitors of serotonin, norepinephrine and/or dopamine, or triple reuptake inhibitors of norepinephrine, serotonin, and dopamine and particularly useful for treating depression, anxiety, or a combination thereof mediated by serotonin or norepinephrine neurotransmission or a combination thereof. They may be also useful in the treatment of other diseases such as genitourinary diseases and pain assocd. with monoamine reuptake inhibitors. Thus, mesylation of 6-(3-Hydroxy-1-phenylpropyl)-1H-indole-3-carbonitrile by methanesulfonyl chloride in the presence of Et3N in THF/CH2Cl2 at 0° for 2.5 h followed by amination with 33% methylamine/ethanol in a sealed tube at 100° for 45 min gave 6-(3-methylamino-1-phenylpropyl)-1H-indole-3-carbonitrile (II). II showed IC50 of 9.4 μM against the binding of [3H]citalopram to human serotonin transporter (hSERT).


IT 938061-95-1P, 3-(3-Methoxy-1H-indazol-4-yl)-3-phenylacrylic acid ethyl ester 938061-96-2P, 3-(3-Methoxy-1H-indazol-4-yl)-N-methyl-3-phenylacrylamide 938061-97-3P, 3-(3-Methoxy-1H-indazol-4-yl)-N-methyl-3-phenylpropionamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 3-amino-1-arylpropylindoles and aza-substituted indoles as biogenic monoamine reuptake inhibitors for treating depression, anxiety, or pain)

RN 938061-95-1 CAPLUS

CN 2-Propenoic acid, 3-(3-methoxy-1H-indazol-4-yl)-3-phenyl-, ethyl ester (CA INDEX NAME)



RN 938061-96-2 CAPLUS

CN 2-Propenamide, 3-(3-methoxy-1H-indazol-4-yl)-N-methyl-3-phenyl- (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 76-05-1

CMF C2 H F3 O2



ACCESSION NUMBER:

2006:194015 CAPLUS

DOCUMENT NUMBER:

144:292768

TITLE:

Preparation of 2,4-di(aminophenyl)pyrimides as

protein

PLK1 inhibitors

INVENTOR(S):

Stadtmueller, Heinz; Engelhardt, Harald; Steegmaier, Martin; Baum, Anke; Guertler, Ulrich; Schoop,

Andreas;

Quant, Jens; Solca, Flavio; Hauptmann, Rudolf;

Reiser,

Ulrich; Zahn, Stephan Karl; Herfurth, Lars

PATENT ASSIGNEE(S):

Boehringer Ingelheim International G.m.b.H., Germany

SOURCE:

PCT Int. Appl., 272 pp.

DOCUMENT TYPE:

CODEN: PIXXD2

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT:

German

PATENT INFORMATION:


1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021544	A1	20060302	WO 2005-EP54089	20050818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006148800	A1	20060706	US 2005-206703	20050817
AU 2005276500	A1	20060302	AU 2005-276500	20050818
CA 2573371	A1	20060302	CA 2005-2573371	20050818
EP 1781640	A1	20070509	EP 2005-777896	20050818
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101044137	A	20070926	CN 2005-80035995	20050818
IN 2007DN00365	A	20070803	IN 2007-DN365	20070115
KR 2007048757	A	20070509	KR 2007-704974	20070228
PRIORITY APPLN. INFO.:			EP 2004-19775	A 20040820
			WO 2005-EP54089	W 20050818

OTHER SOURCE(S):

MARPAT 144:292768

GI



AB Title compds. I [W = N, CR2; X = O, S, NR1a; Y = CH, N; Z = H, halo, NO2, etc.; A = mono or bicyclic aryl ring (sic); R1, R1a = H, CH3; R2 = H, halo, OR4, etc.; R4, Rb, Rc = H, halo, =O, etc.; R4 = H, alkyl, alkenyl, etc.; R3 = CON(R1)LQ2Q3R7, N(R1)COLQ2Q3R7, etc.; L = bond, alkyl, alkenyl, etc.; Q2, Q3 = bond, alkyl, alkenyl, etc.; R7 = H, alkyl, alkenyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared

For example, coupling of chloropyrimidine II and 7-amino-2,3-dihydroisindol-1-one afforded diaminophenylpyrimidine III in 33% yield. Compds. I are claimed to be useful for the treatment of diseases characterized by excessive or anomalous cell proliferation.

IT 878143-73-8P 878143-74-9P 878152-65-9P


878152-67-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)


RN 878143-73-8 CAPLUS

CN Benzamide, 4-[[4-[(2,3-dihydro-1-methyl-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



RN 878143-74-9 CAPLUS

CN Benzamide, 4-[[4-[(2,3-dihydro-1-methyl-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 878152-65-9 CAPLUS

CN Benzamide, 4-[[4-[(1-ethyl-2,3-dihydro-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-[trans-4-(4-morpholinyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

Et

RN 878152-67-1 CAPLUS

CN Benzamide, 4-[[4-[(2,3-dihydro-1-(2-hydroxyethyl)-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-[trans-4-(4-morpholinyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2005:1004761 CAPLUS
DOCUMENT NUMBER: 143:306497
TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotsugu; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 169 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,			
ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, ML, PL, PT, RO, SE, SI, SK, TR			
CN 1950389	A	20070418	CN 2005-80014287	20050303
BR 2005008243	A	20070724	BR 2005-8243	20050303
MX 2006PA09899	A	20061211	MX 2006-PA9899	20060831
US 2007191289	A1	20070816	US 2006-591757	20060901
IN 2006DN05080	A	20070622	IN 2006-DN5080	20060904
PRIORITY APPLN. INFO.:			JP 2004-61426	A 20040304
			WO 2005-JP4145	W 20050303


OTHER SOURCE(S): MARPAT 143:306497
GI



AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridine-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) (R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxy-C1-6 alkyl, C2-6 alkenyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkenyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, H; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S-, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2) are prepared. These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hyperglycemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.


IT 864845-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia]
RN 864845-14-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



IT 864845-69-2P 864845-70-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
[preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia]
RN 864845-69-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-(phenylmethoxy)ethyl)-4-(phenylmethyl)-1H-indazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)


Absolute stereochemistry.



RN 864845-70-5 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2004:1154679 CAPLUS
DOCUMENT NUMBER: 142:93813
TITLE: A preparation of indazole and pyrazolopyridine derivatives, useful as JNK inhibitors
INVENTOR(S): Ford, Rhonan; Leroux, Frederic; Stocks, Michael; Swahn, Britt-Marie
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004/113303	A1	20041229	WO 2004-SE1015	20040623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GR, GU, HK, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			SE 2003-1906	A 20030626
OTHER SOURCE(S):		MARPAT 142:93813		
GI				




AB The invention relates to a preparation of indazole and pyrazolopyridine derivs. of formula I (wherein: X is N, CH, C-NO2, or C-CN, etc.; R1 is O-CH2-aryl, NHC(O)-(H/alkyl), or NH2, etc.; R2 is H, O-aryl, or NH-aryl, etc.; R3 is H or NH-Ar; Ar is benzene optionally substituted with one or more of alkyl, fluoroalkyl, hydroxyalkyl, etc.), useful as JNK inhibitors. For instance, (benzylamino)pyrazolopyridine derivative II (R4 = 2,5-dimethoxybenzyl) was prepared via phenoxylation of 2-chloro-4-methoxy-3-pyridinecarbonitrile, heterocyclization with hydrazine, and subsequent reductive N-benzylation


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
of the obtained aminopyrazolopyridine deriv. II (R4 = H) by 2,5-dimethoxybenzaldehyde. Typical Ki values of the invention compds. of formula I are in the range of about 0.001 to about 10000 nM.
IT 816454-64-5P, 3-[(2-chlorobenzyl)oxy]-4-phenoxy-1H-indazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole and pyrazolopyridine derivs. useful as JNK inhibitors)
RN 816454-64-5 CAPLUS
CN 1H-Indazole, 3-[(2-chlorophenyl)methoxy]-4-phenoxy- (CA INDEX NAME)



IT 816454-68-9P, 4-Phenoxy-1,2-dihydro-3H-indazol-3-one
816454-70-3P, Ethyl 3-oxo-4-phenoxy-2,3-dihydro-1H-indazole-1-carboxylate 816454-73-6P, Ethyl 3-[(2-chlorobenzyl)oxy]-4-phenoxy-1H-indazole-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole and pyrazolopyridine derivs. useful as JNK inhibitors)
RN 816454-68-9 CAPLUS
CN 3H-Indazol-3-one, 1,2-dihydro-4-phenoxy- (CA INDEX NAME)




RN 816454-70-3 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 2,3-dihydro-3-oxo-4-phenoxy-, ethyl ester (CA INDEX NAME)



RN 816454-73-6 CAPLUS

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Indazole-1-carboxylic acid, 3-[(2-chlorophenyl)methoxy]-4-phenoxy-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 1972:106429 CAPLUS
 DOCUMENT NUMBER: 76:106429
 ORIGINAL REFERENCE NO.: 76:17113a,17116a
 TITLE: Light-sensitive color photographic film containing an indazolone derivative as purple coupler
 INVENTOR(S): Boie, Immo; Schulte, Walter; Pelz, Willibald
 PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.
 SOURCE: Ger. Offen., 21 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2032171	A	19720113	DE 1970-2032171	19700630
BE 769116	A2	19711228	BE 1971-3192	19710628
GB 1335603	A	19731031	GB 1971-30340	19710629
FR 2100089	A5	19720317	FR 1971-24008	19710630
PRIORITY APPLN. INFO.:		DE 1970-2032171	A	19700630

AB Previously used indazolones yield, with color developer p-H₂NC₆H₄NBu(CH₂)₄SO₃H, dyes with undesirable absorption maximum >580 nm. Brilliant dyes with absorption maximum at 550-570 nm and stable to moist

heat can be obtained with nondiffusing indazolones having a C₈-20 alkoxy, aralkoxy, benzyloxy or benzyl substituent with C₈-20 alkyl groups. Thus, 6-cetoxyindazolone is obtained from 2-nitro-4-hydroxybenzoic acid by etherification with C₁₆H₃₃Br, reduction of the NO₂, diazotization and reduction to the o-hydrazinobenzoic acid, which undergoes ring closure when boiled in 2N KOH.

IT 36498-68-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 36498-68-7 CAPLUS
 CN 3H-indazol-3-one, 4-[(4-hexadecylphenyl)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:16:25 ON 12 DEC 2007)

FILE 'REGISTRY' ENTERED AT 13:17:14 ON 12 DEC 2007

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 17 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:17:40 ON 12 DEC 2007

L4 5 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

27.29

199.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.90

-3.90

STN INTERNATIONAL LOGOFF AT 13:18:51 ON 12 DEC 2007

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1277	(514/303,514/415,546/119,548/361.1).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 14:01
L2	0	("l1andnitrogenous").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 14:01
L3	7	l1 and nitrogenous	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 14:01